Table 1 Baseline characteristics and therapy of the cohort

From: Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma

Characteristics Entire cohort (n=28)
Male, n (%) 15 (53%)
Age at HCT, median (range) 25 (15–49)
Stage at Dx, n (%)
  II 7 (25)
  III 6 (21)
  IV 15 (54)
Constitutional Symptoms at Dx, n (%) 20 (71)
Bulky Disease at Dx, n (%) 8 (29)
Front Line Treatment, n (%)
  ABVD 23 (82)
  ABVD → EscBEACOPP 4 (14)
  Other 1 (4)
IFRT, n (%) 5 (18)
Refractory (≤ 3 months remission), n (%) 12 (43)
Time to relapse, median months (range) 7.9 (1.9–133)
IGEV-Bv order of salvage, n (%)
  First 14 (50)
  Subsequent 14 (50)
No. of salvage cycles, median (range) 2 (2–6)
Number of cycles at stem cell collection, median (range) 2 (1–5)
Days of collection, median (range) 1 (1–2)
CD34x106/kg collected, median (range) 13.6 (2.8–44.8)
PET/CT status post IGEV-Bv, n (%)
  Complete metabolic response 20 (71)
  Partial metabolic response 7 (25)
  Stable disease 1 (4)
 Median follow-up, months (range) 17 (0–65)